ArticleAdvanced functional materials2021
Nanogel-facilitated Protein Intracellular Specific Degradation through Trim-Away.
Article in Advanced functional materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics.Chemical reviews · 2025Review
- COPZ1: an example of non-oncogene addiction in human tumors.Frontiers in pharmacology · 2025Review
- Recent Advances in Transparent Electrodes and Their Multimodal Sensing Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Nanogels: Recent Advances in Synthesis and Biomedical Applications.Nanomaterials (Basel, Switzerland) · 2024Review
- Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins.Nature communications · 2024Article
- Bioreversible Anionic Cloaking Enables Intracellular Protein Delivery with Ionizable Lipid Nanoparticles.ACS central science · 2024Article
- Intracellular Protein Delivery: Approaches, Challenges, and Clinical Applications.BME frontiers · 2024Review
- A Tunable Soft Silicone Bioadhesive for Secure Anchoring of Diverse Medical Devices to Wet Biological Tissue.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy.Blood advances · 2023Article
- Beyond canonical PROTAC: biological targeted protein degradation (bioTPD).Biomaterials research · 2023Review
- Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges.Pharmaceutics · 2023Review
- Glutathione-Scavenging Nanoparticle-Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Antiviral PROTACs: Opportunity borne with challenge.Cell insight · 2023Review
- A Comprehensive Pan-Cancer Analysis of the Regulation and Prognostic Effect of Coat Complex Subunit Zeta 1.Genes · 2023Article
- Biologics-based degraders - an expanding toolkit for targeted-protein degradation.Current opinion in biotechnology · 2022Review
- TRIM family contribute to tumorigenesis, cancer development, and drug resistance.Experimental hematology & oncology · 2022Review
- Targeted protein degradation by Trim-Away using cell resealing coupled with microscopic image-based quantitative analysis.Frontiers in cell and developmental biology · 2022Article
- Targeted protein degradation in mammalian cells: A promising avenue toward future.Computational and structural biotechnology journal · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Recently discovered "Trim-Away" mechanism opens a new window for fast and selective degradation of endogenous proteins. However, the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.